Objective To explore the effect of combination of dibutyryl cyclic adenosine calcium(dbc AMP-Ca and metoprolol sustained-release tablets in the treatment of chronic heart failure（CHF） with arrhythmia on symptom relief and improvement of cardiac function. Methods Eighty-two cases of patients with CHF and arrhythmia who were admitted to our hospital from June 2019 to June 2020 were collected

randomly divided into two groups according to the random number table method. Forty-one cases of patients in the control group were treated with dbc AMP-Ca

and41 cases of patients in the observation group were treated with dbc AMP-Ca combined with metoprolol sustained-release tablets. The indicators of cardiomyocyte damage

symptom relief and cardiac function were compared between the two groups. Results In the observation group

the N-terminal pro-brain natriuretic peptide（NT-pro BNP） and cardiac troponin I（c Tn I） after treatment were lower than the control group（p<0.05）. In the observation group

the maintenance rate of sinus rhythm at 1 month

3 months

and 6 months after treatment were higher than the control group（p<0.05）. In the observation group

the left ventricular end diastolic volume（LVEDV） after treatment was lower than the control group

the left ventricular ejection fraction（LVEF） and cardiac output（CO） were higher than the control group（p<0.05）

and in the observation group

the classification of cardiac function was better than the control group（p<0.05）. Conclusions The combination of dbc AMP-Ca and metoprolol sustained-release tablets in the treatment of CHF with arrhythmia can effectively reduce myocardial damage

maintain sinus rhythm

as well as further improve the heart function of patients.